Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression
This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deeper into safety and efficacy data, the trial’s design and protocol, as well as the company’s plans for future development of the candidate in PPD and beyond.